eli lilly glp-1 pill data Lilly's oral may help people with Type 2 diabetes lose 'significant' weight, study finds Lilly's GLP-1 portfolio gains ground
Description
Expert-backed advice inside.
Once Monthly GLP-1 Maridebart cafraglutide is an investigational once-monthly injectable drug developed by Amgen that shows significant promise for treating obesity and Type 2 diabetes
The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.
Methods Sixteen participants with type 2 diabetes that was relatively well-controlled by metformin monotherapy were studied on four separate days in a crossover design
A new study based on real world data found a possible protective effect against multiple sclerosis for some of new weight loss medications.
